Candidemia is the main invasive fungal disease among hospitalized patients. Several breakthrough candidemia (BrC) cases have been reported, but few studies evaluate the epidemiology, risk factors, molecular characterization, antifungal susceptibility profile and outcome of those patients, especially in developing countries and including patients using broad spectrum antifungals. We conducted a retrospective study from 2011 to 2016, including patients aged 12 years or older with candidemia. Epidemiological characteristics and risk factors for candidemia were evaluated and compared with patients with BrC using univariate and multivariate analysis. Sequential Candida isolates from BrC were identified by internal transcribed spacer sequencing, genotyped with amplified fragment length polymorphism fingerprinting (AFLP), and tested for antifungal susceptibility. From 148 candidemia episodes, 27 breakthrough episodes (18%) were identified, with neutropenia and mucositis being independent risk factors for BrC. Candida nonalbicans was more frequent in the BrC group (P < .001). AFLP showed high correlation with conventional methods of identification among breakthrough isolates and a high genetic similarity among isolates from the same patient was observed. C. albicans was the most susceptible species with low MIC values for all antifungal agents tested. In 
Introduction
Bloodstream infections due to Candida species are the most frequent invasive fungal disease among hospitalized patients, with increasing incidence and high attributable morbidity and mortality. [1] [2] [3] In a recent survey of healthcare associated infections in US hospitals, Candida sp. was the most frequent pathogen identified from primary bloodstream infections. 4 As new strategies using systemic antifungal agents have been used for prevention and early treatment of candidemia in high-risk patients 5, 6 ; breakthrough cases are more frequently being reported even with broad spectrum antifungal agents. 7 These cases are associated with emergence of resistance, frequent use of more toxic antifungal agents for treatment and poor outcome. [8] [9] [10] [11] Most data available in the literature on breakthrough candidemia (BrC) are based on case reports and few epidemiologic and risk factors studies from developed countries, with limited data about breakthrough infections in patients receiving broad spectrum antifungal agents, particularly echinocandins. Considering the increasing number of cases of BrC, and its consequences in clinical practice, we aimed to perform a retrospective study analyzing the epidemiology, risk factors and outcome of breakthrough candidemia in two different centers in southern Brazil after the introduction of an echinocandin in the routine use of both hospitals.
Methods

Study design
We conducted a retrospective analysis of candidemia between February 2011 and February 2016 in patients older than 12 years and admitted to two different tertiary care hospitals in Southern Brazil (one public university hospital with 426 beds and a private hospital with 230 beds). Candidemia was defined as at least one Candida sp. positive blood culture per patient with clinical signs of infection. Breakthrough candidemia (BrC) was defined as the occurrence of candidemia in a patient having received at least three consecutive days of systemic antifungal therapy. 12 
Clinical data
Medical records were used to access patients' clinical information. Previous antifungal use was classified as prophylaxis and treatment of possible, probable or proven of invasive fungal disease (IFD), 13 and empirical use in patients at risk for IFD. Risk factors for candidemia were evaluated in the week preceding the diagnosis, including antimicrobial and corticosteroids use, neutropenia (absolute neutrophil count <500/mm 3 ), presence of a central venous catheter (CVC) and type of catheterization (long-term or short-term), total parenteral nutrition (TPN), pancreatitis, hemodialysis, mucositis, and abdominal surgery during the present admission. Catheter related candidemia was defined based on the growth of the same Candida species from at least one percutaneous blood culture and from a culture of the catheter tip. 14 Mucositis was defined according to the assistant physician evaluation, as mucosal damage secondary to chemotherapy occurring in the oral cavity, esophageal regions and other areas of the gastrointestinal tract. 15 Intensive care unit (ICU) admission was considered if the patient was in or transferred to an ICU in the first 24 hours since the diagnosis of candidemia. Shock was defined as circulatory dysfunction with the necessity of vasopressor drugs to maintain adequate blood pressure in the first 24 hours since the diagnosis of candidemia. 16 The total number and proportion of BrC cases were analyzed during the study period to detect potential epidemiological trends along the study period. Appropriateness of antifungal therapy was evaluated in the first 24 hours of candidemia and considered appropriate when the patient received adequate antifungal therapy based on further species identification and in vitro susceptibility. Outcome evaluation was based on thirty day and inpatient overall mortality.
Isolation and conventional identification
Candida positive blood cultures were recovered by the BACTEC 9240 system (Becton-Dickinson Microbiology Systems, Franklin Lakes, New Jersey) or BacT/Alert (BioMerieux SA, Marcy L'Etoile, France) blood culture system and identified using API 20C AUX (bioMérieux-Vitek) or VITEK 2 (bioMérieux). Breakthrough candidemia viable isolates were retrieved from frozen storage (−20
• C) and submitted to molecular characterization as described below.
Molecular characterization
Extraction of genomic DNA and amplified fragment length polymorphism (AFLP) fingerprinting were performed as described previously. 17 
Results
Clinical data
During the study period, 149 candidemia episodes were identified; one patient was excluded due to unavailable clinical data. Twenty-seven episodes were classified as BrC (18%); the remaining 121 patients were the control group (non-BrC). Proportion of breakthrough infections ranged from 10 to 30%, without an epidemiological trend along the study period. Patients characteristics are described in Table 1 . Detailed characteristics of BrC patients are available as supplementary results (Supplementary information S1). Among the BrC patients, 12 (44%) were receiving micafungin in the moment that the breakthrough infection occurred, 7 (26%) fluconazole, 6 (22%) voriconazole, 1 (4%) amphotericin B, and 1 (4%) received combined therapy with micafungin and voriconazole. The main indications of antifungal use were prophylaxis of IFD in 16 (59%) patients, therapy for possible, probable or proven invasive aspergillosis in eight (30%) cases, or empirical use in febrile neutropenia in three (11%) patients. The average time of exposure until the BrC was 16 days (range: 3-65, median 13).
Risk factor prevalence and analysis are shown in Table 2 . Neutropenia (P < .001), corticosteroid (P = .011) use, and mucositis (P < .001) were significant risk factors for BrC in univariate analysis. Patients with BrC had more risk factors when compared with the control group (4.03 ± 1.01 SD vs. 2.99 ± 1.28 SD; P < .001). Type of catheterization was different between the groups, with 87% of patients having long-therm catheters in the BrC group, compared to 13% in the non-BrC group (P = .002). Nine (39%) of the patients had their CVC removed and sent to culture in the BrC group, and 52 (52%) in the control group (P = .242). We could define only one CVC related infection in the BrC group (4%), compared with 24 episodes (20%) in the control group (P = .031). Previous abdominal surgery, pancreatitis, dialysis, ICU admission, and the presence of shock at presentation were also more frequent in the non-BrC group. After multivariate analysis, neutropenia (P < .001; OR = 4.20-66.05) and mucositis (P = .002; OR = 2.72-79.68) persisted as independent risk factors.
Regarding appropriateness of antifungal therapy, only eight patients (7%) of the non-BrC group were receiving adequate empirical antifungal therapy in the first 24 hours of candidemia, compared to 20 patients (74%) in the BrC group (P < .001).
Candida species
The species distribution is shown in Table 3 . Two isolates initially defined as C. tropicalis and C. krusei in conventional identification were redefined as C. parapsilosis and C. tropicalis, respectively, after molecular characterization. We also found one isolate of C. orthopsilosis misidentified as C. parapsilosis by the conventional identification.
In the control group Candida albicans (52%) was the most frequent species isolated, followed by C. tropicalis (15%) and C. glabrata (15%), while for BrC group C. parapsilosis (19%) and C. tropicalis (19%) were most commonly recovered. Candida non-albicans species were more frequent in the BrC group (P < .001), without significant differences between individual species.
AFLP fingerprinting
The resulting dendrogram for AFLP fingerprinting analysis is shown in Figure 1 . The analysis revealed the presence of six major clusters, divided cording to the species. Candida guilliermondii isolates were segregated into two subclusters, one of them containing all six isolates CG33 from the same patient (patient number 5). The group of C. parapsilosis species was also divided into two subclusters: a major one containing 4 isolates from 3 patients (patient numbers 6, 10, 19), showing high similarity (≥95%) among them. C. tropicalis cluster had two subclusters, each one containing two isolates from the same patient (CK26I-II, patient number 9; CTR89I-II, patient number 13). Candida albicans cluster was segregated in three subclusters: the major one contained a group of three isolates from the same patient (CA307I-III, patient number 15) and two from distinct cases of breakthrough candidemia (CA296I, patient number 2; CA334, patient number 17); another subcluster with only one isolate (CA332, patient number 01); and the last subcluster with 1 isolate of C. orthopsilosis (ACT, patient number 23) was grouped with C. albicans but showing differences in dominant markers. At least, the C. glabrata cluster showed two subclusters each one grouped isolates from the same patient (CGL64I-IV, patient number 4; CGL72I-II, patient number 11).
Antifungal susceptibility profiles
Thirty-three viable isolates from 19 BrC patients were used for antifungal susceptibility testing; results are presented in Table 4 . Seven Candida isolates showed high MICs of fluconazole, voriconazole, anidulafungin, and micafungin. Most isolated were from patients under azole use (n = 6/7 and >32 μg ml −1 , respectively. In addition, two C. tropicalis isolates were resistant to fluconazole, voriconazole, and anidulafungin and had high MIC values for itraconazole and isavuconazole (>32 μg ml −1 ).
Discussion
As the number of severely immunossupressed patients susceptible to IFD increases, more patients are candidates to receive systemic antifungal drugs for treatment and prophylaxis. Besides reducing the incidence and mortality due to IFD, antifungal exposure is also clearly associated with breakthrough infections. Patient factors, emergence of resistance, and antifungal prescribing patterns may explain the occurrence of these cases. We identified a higher proportion of breakthrough infections (18%) among all candidemia episodes when compared with similar previously reported studies that found around 10% of BrC. 7,9,12 Cuervo et al. reported a trend toward increasing incidence of breakthrough cases in more recent years, although this tendency was not observed in our study. Most of our patients were young (average 35.3 years), severely immunossupressed, with malignant hematological diseases or submitted to hematologic stem cell transplantation, with multiple risk factors for candidemia. Although CVC was initially described as an important issue of BrC, 23 further studies did not confirm this hypothesis, identifying neutropenia, increased antibiotic exposure and corticosteroid use as risk factors for BrC. 9, 12 As the gastrointestinal tract was considered to be the main source of bloodstream infection in those cases, the role of mucositis should be further evaluated. 12 Raad et al. found that previous chemotherapy ≤1 month before the onset of candidemia was a predictor of noncatheter source of infection in patients with cancer. 24 The findings of the present study are consistent with these observations, as we could identify only one case of CVC related BrC, and after multivariate analysis, mucositis was identified as an independent risk factor for BrC, along with neutropenia, corroborating the important role of the gastrointestinal tract in breakthrough infections. Candida biofilm formation in the gut, preventing the antifungal to achieve adequate concentrations in the yeast cells inside the biofilm, probably play an important role in the pathophysiology of BrC with gastrointestinal translocation to the bloodstream, and resistance development in patients receiving antifungal therapy. 25, 26 The type of catheterization in the BrC patients also may contribute to the low incidence of catheter related bloodstream infections detected, as long-therm catheters are associated with lower risk of infection over time as compared to short-term catheters. 27 It is tempting to consider the hypothesis that the antifungal agent might have influenced the occurrence of BrC, as a significant number of cases occurred in patients receiving micafungin (44%). During the study period, micafungin was frequently used as prophylaxis of IFD due to the high incidence of invasive aspergillosis in both centers. 28 In studies involving high risk hematologic patients, echinocandin use was identified as an independent risk factor for breakthrough IFD, especially regarding yeasts.
29,30
The lack of data on antifungal prescribing patterns and the denominator population in our study do not allow us to analyze the contribution of antifungal choice in the occurrence of breakthrough infection. Nevertheless, this hypothesis should be evaluated in further studies. The species distribution in the BrC group demonstrates a shift to non-albicans species, consistent with previous reports, 7, 9, 12 without predominance of one species over the others. Previous reports from developed countries showed a higher prevalence of C. glabrata and C. krusei in BrC, 9 which was not observed in the present study, possibly due to the lower frequency of C. glabrata and C. krusei in Latin American hospitals.
2 AFLP was previously demonstrated as a reliable method for the identification of medically important Candida species. 31 In our study, AFLP fingerprinting identification had 85% of correlation with conventional methods. Two isolates defined as C. tropicalis and C. krusei by biochemical methods were identified as C. parapsilosis and C. tropicalis by AFLP fingerprinting, respectively. Herkert and colleagues 32 found discrepancies between biochemical 40 and whole genome sequencing. 41 In invasive candidiasis, as in candidemia cases, the correct identification of the causative agent to the species level is essential, as different species show different patterns of antifungal susceptibility, guiding the therapeutic choice for each case. Regarding breakthrough cases, the correct identification is even more important in understanding issues that contributed to the breakthrough infection, such as development of resistance. Antifungal resistance was identified in 26% of all cases of BrC, mainly in patients receiving fluconazole, but also in patients receiving voriconazole or micafungin. Fluconazole exposure was associated with two isolates of C. guilliermondii with high MICs (patients 3 and 5 -Supplementary Appendix), and one isolate of C. glabrata and C. krusei each (patients 4 and 7). Two patients with voriconazole treatment for possible invasive aspergillosis developed candidemia due to non-susceptible isolates. Patient 9 on voriconazole therapy was earlier exposed to fluconazole prophylaxis, and also received a 3-day empirical course of micafungin the week before C. tropicalis infection occurred, suggesting the origin of the emergence of multidrug resistance in this case. Patient 10 developed infection due to C. parapsilosis after previous exposure to fluconazole prophylaxis and voriconazole treatment which most likely contributed to the emergence of resistance to these agents, and cross-resistance mechanism could explain the elevated MICs observed to itraconazole and posaconazole. Three patients receiving micafungin had C. parapsilosis infection. Though MICs of these isolates were in the susceptible range, C. parapsilosis MICs of echinocandins are intrinsically much higher than those of C. albicans. This difference is not translated into significant clinical failure during echinocandin treatment, but may play a role in breakthrough infections. 10 Finally, in patient 16 we could demonstrate that the C. glabrata isolate was resistant to fluconazole and micafungin, used in low dose for prophylaxis.
11
Regarding disease severity, BrC patients were more frequently hospitalized on medical wards than in ICUs, and there was a trend for decreased septic shock at presentation in BrC group. These findings together may suggest that the severity of illness in these cases could be lower. Despite some reports suggests that previous antifungal exposure and development of resistance could be associated with less virulent Candida species, 7, 42 other animal and clinical studies found the opposite, specially regarding C. glabrata infections. [43] [44] [45] It is also important to consider that most BrC patients were receiving appropriate antifungal therapy in the moment candidemia occurred, possibly attenuating the clinical impact of the infection in this scenario, as timely adequate antifungal treatment is likely to be associated with improved clinical outcomes. 46 However, in-hospital and 30-day mortality rates did not differ in the present study. The low number of BrC cases, involving different Candida species, does not allow us to make any adequate comparison regarding virulence and outcomes in our cases of breakthrough candidemia.
The fact that this was a retrospective study, with a low number of breakthrough cases is a limitation, common to similar previous reports. The absence of data regarding antifungal consumption did not allow us to estimate the role of antifungal choice on breakthrough infections. Voriconazole therapeutic drug monitoring was not available during the study period in both centers, not permitting us to detect a possible contribution to breakthrough infection in patients with subtherapeutic voriconazole serum concentrations. Moreover, catheter related infection could not be dismissed in all patients, possibly underestimating the potential contribution of catheter related infection in both groups. In addition, because 30% of the isolates were not available for antifungal susceptibility testing, antifungal resistance might be underestimated.
In conclusion, breakthrough infections occurred mainly in severely immunossupressed patients, with neutropenia and mucositis identified as independent risk factors in multivariate analysis. The role of specific antifungal agents should be further evaluated as a risk factor for breakthrough infections, as a high number of patients received micafungin in our study, and this may have a significant impact on resistance emergence and salvage therapy. Candida non-albicans species were more commonly isolated from breakthrough cases, including species resistant to earlier used antifungal drugs, the majority being azoles. AFLP had high correlation with conventional methods of Candida spp. identification among breakthrough isolates, with consecutive isolates from the same patients being genetically related. The low number of critically ill patients and a trend to lower number of patients with shock in the BrC group may suggest a less severe illness in these patients, possibly due to early appropriate therapy in this group. Thirty-day and in-patient mortality did not differ significantly between the groups.
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